{"id":254284,"date":"2012-07-13T23:11:38","date_gmt":"2012-07-13T23:11:38","guid":{"rendered":"http:\/\/www.eugenesis.com\/ember-therapeutics-announces-cell-publication-of-key-beige-fat-discovery-technology-licensed-from-the-dana-farber\/"},"modified":"2012-07-13T23:11:38","modified_gmt":"2012-07-13T23:11:38","slug":"ember-therapeutics-announces-cell-publication-of-key-beige-fat-discovery-technology-licensed-from-the-dana-farber","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/ember-therapeutics-announces-cell-publication-of-key-beige-fat-discovery-technology-licensed-from-the-dana-farber.php","title":{"rendered":"Ember Therapeutics Announces Cell Publication of Key Beige Fat Discovery; Technology Licensed from the Dana-Farber &#8230;"},"content":{"rendered":"<p><p>    BOSTON--(BUSINESS WIRE)--  <\/p>\n<p>        Ember Therapeutics, Inc., a company harnessing    breakthroughs in brown fat biology and insulin sensitization to    revolutionize the treatment of metabolic disease, today    announced the publication of key data isolating beige fat    cells and describing their unique genetic profile for the first    time. The study, published in the journal Cell, found    that beige fat cells - which burn caloric energy like brown    fat cells - are specifically targeted by the hormone        irisin.  <\/p>\n<p>    This breakthrough beige fat research was led by     Bruce Spiegelman, Ph.D., professor of cell biology,    Dana-Farber Cancer Institute, Harvard Medical School, and a    co-founder of Ember, and was funded by the National Institutes    of Health, the JPB Foundation and the American Heart    Association. Ember recently completed a licensing agreement    with the Dana-Farber Cancer Institute for intellectual property    related to this beige fat discovery.  <\/p>\n<p>    This study from the lab of one of Embers scientific    co-founders sheds additional light on the complex matter of    brown, beige and white fat, said Louis Tartaglia, Ph.D.,    president and interim chief executive officer of Ember.    Importantly, the data provides further understanding of the    nature of brown fat in humans, thus allowing more rational    approaches to effectively and safely develop drugs that augment    this tissue in patients. Ember is aggressively working on    translating world-class research in the brown fat space to meet    the critical need for novel approaches to metabolic diseases.  <\/p>\n<p>    The newly isolated beige fat cells are a type of brown fat cell    that is distinct from the classic brown fat most highly studied    in small mammals and human infants. Beige fat cells are    produced from white fat depots when triggered by specific    conditions such as exercise and cold. Similar to brown fat,    beige fat burns caloric energy, whereas white fat stores excess    energy.  <\/p>\n<p>    The paper, Beige Adipocytes are a Distinct Type of Thermogenic    Fat Cell in Mouse and Human, is now available     online and will publish in the print edition of Cell    on July 20.  <\/p>\n<p>    About Ember Therapeutics, Inc.  <\/p>\n<p>    Ember Therapeutics is a product-focused company harnessing    breakthroughs in brown fat biology and insulin sensitization to    revolutionize the treatment of metabolic disease. Todays    rising epidemic of obesity and Type 2 diabetes coupled with the    lack of innovation in the industrys metabolic disorder    treatment pipeline underscores the need for novel,    peripherally-acting treatments with improved safety profiles.    Embers unique approach leverages recent research breakthroughs    in brown fat biology to develop a pipeline of proprietary large    and small molecules designed to amplify the bodys innate    ability to efficiently burn fuels like glucose. Embers    expertise is also driving the development of the next    generation of highly selective insulin sensitizers that have    robust anti-diabetic effects, but lack the serious side effects    of currently approved insulin sensitizers. Ember is a private    company launched in 2011 by renowned scientific founders, an    experienced leadership team and Third Rock Ventures. For more    information, please visit     <a href=\"http:\/\/www.embertx.com\" rel=\"nofollow\">http:\/\/www.embertx.com<\/a>.  <\/p>\n<\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/ember-therapeutics-announces-cell-publication-143000668.html;_ylt=A2KJNTsiqwBQhGAA4TX_wgt.\" title=\"Ember Therapeutics Announces Cell Publication of Key Beige Fat Discovery; Technology Licensed from the Dana-Farber ...\">Ember Therapeutics Announces Cell Publication of Key Beige Fat Discovery; Technology Licensed from the Dana-Farber ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> BOSTON--(BUSINESS WIRE)-- Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data isolating beige fat cells and describing their unique genetic profile for the first time. The study, published in the journal Cell, found that beige fat cells - which burn caloric energy like brown fat cells - are specifically targeted by the hormone irisin. This breakthrough beige fat research was led by Bruce Spiegelman, Ph.D., professor of cell biology, Dana-Farber Cancer Institute, Harvard Medical School, and a co-founder of Ember, and was funded by the National Institutes of Health, the JPB Foundation and the American Heart Association <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/ember-therapeutics-announces-cell-publication-of-key-beige-fat-discovery-technology-licensed-from-the-dana-farber.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254284","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254284"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254284"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254284\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}